Logo

Novartis and Molecular Partners Reports Results of Ensovibep (MP0420) in P-II (EMPATHY) Clinical Trial for the Treatment of COVID-19

Share this

Novartis and Molecular Partners Reports Results of Ensovibep (MP0420) in P-II (EMPATHY) Clinical Trial for the Treatment of COVID-19

Shots:

  • Part A of the P-II (EMPATHY) trial evaluates ensovibep (75/225/600mg, IV) vs PBO in 407 patients with COVID-19
  • The trial met the 1EPs i.e., reduction in viral load @8days for all doses. The 2EPs includes hospitalization, ER visits related to COVID-19, or death, 78% reduction in risk of events, no deaths in patients treated with ensovibep while all doses were well-tolerated with no safety issues
  • Novartis will exercise its option to in-license ensovibep, accelerate manufacturing & plans to seek expedited regulatory authorizations globally through US FDA’s EUA while Molecular Partners will receive a $162.85M milestones along with 22% royalty on sales of ensovibep in commercial territories

Ref: Novartis | Image: Novartis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions